Hepatitis C virus-mediated angiogenesis: molecular mechanisms and therapeutic strategies.
Angiogenesis is an essential process for organ growth and repair. Thus, an imbalance in this process can lead to several diseases including malignancy. Angiogenesis is a critical step in vascular remodeling, tissue damage and wound healing besides being required for invasive tumor growth and metastasis. Because angiogenesis sets an important point in the control of tumor progression, its inhibition is considered a valuable therapeutic approach for tumor treatment. Chronic liver disease including hepatitis C virus (HCV) infection is one of the main cause for the development of hepatic angiogenesis and thereby plays a critical role in the modulation of hepatic angiogenesis that finally leads to hepatocellular carcinoma progression and invasion. Thus, understanding of the molecular mechanisms of HCV-mediated hepatic angiogenesis will help design a therapeutic protocol for the intervention of HCV-mediated angiogenesis and subsequently its outcome. In this review, we will focus on the molecular mechanisms of HCV-mediated hepatic angiogenesis and the related signaling pathways that can be target for current and under development therapeutic approaches.
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Mohamed
M
Hassan
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Denis
D
Selimovic
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Abdelouahid
A
El-Khattouti
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Martine
M
Soell
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Hanan
H
Ghozlan
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Youssef
Y
Haikel
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Ola
O
Abdelkader
Mohamed Hassan, Abdelouahid El-Khattouti, Cancer Institute, University of Mississippi Medical Center, Jackson, MS 39216, United States.
Mosaad
M
Megahed
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000098:blood supply / Q000517:prevention & control / Q000821:virology; D016174:Hepacivirus / Q000378:metabolism / Q000472:pathogenicity*; D006526:Hepatitis C / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D008099:Liver / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism; D008113:Liver Neoplasms / Q000098:blood supply / Q000517:prevention & control / Q000821:virology; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic; D015398:Signal Transduction
D020533:Angiogenesis Inhibitors
Angiogenesis; Hepatitis C virus; Hepatocellular carcinoma; Signaling pathway; Therapy